Violet-Blue Light Inactivation of Bacteria in Chronic Wounds

Status Recruiting

Clinical Trial Summary

This four-week prospective clinical investigation will assess the safety and feasibility of a medical device without CE-marking. The medical device is a light-emitting-diode (LED) and is manufactured by VulCur MedTech Aps. Violet-blue light treatment is tested on a total of twenty-two patients with chronic wounds, divided into three groups, each group only receiving one dosage. Three dosages (low, medium and high) of violet-blue light treatment is tested. ID 1-7 are assigned to the low group, ID 8-15 are assigned to medium group and ID 16-22 are assigned to the high dosage group.

Clinical Trial Description

This is as prospective safety and feasibility clinical trial investigating violet-blue light treatment on chronic wounds. This clinical trial runs from Q3 2022 - Q2 2023. Twenty-two patients with chronic wounds will be included (n = 22) for a study-period of four weeks. Week 1 includes one baseline visit. Through Week 2,3 and 4 treatment is given six times with a span of 24-72 hours between every treatment visit. Week 4 includes one follow up-visit. Patients entering the study are assigned to three light dosage groups (low, medium and high) according to their study ID. ID 1-7 are assigned to the low group, ID 8-15 are assigned to medium group and ID 16-22 are assigned to the high dosage group. Between each dosage of light, there will be an evaluation of primary and secondary endpoints by the sponsor and the principal investigator. Light dosage is only escalated should this evaluation be deemed safe. To determine treatment safety skin reactions are assessed after treatment at: 0 minutes, 30 minutes, 24 hours, 48 hours, 5th treatment visit and at follow-up. Adverse Events and Adverse Device Events are evaluated at every visit for every dosage, feasibility is evaluated at follow-up for both patient and investigator. This investigation complies with the Good Clinical Practice concerning medical devices and follows the ISO standard DS/EN 14 155 and the Declaration of Helsinki ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05739058
Study type	Interventional
Source	Bispebjerg Hospital
Contact	Frederik Plum, MD
Phone	+4529671247
Email	frederik.plum@regionh.dk
Status	Recruiting
Phase	N/A
Start date	March 22, 2023
Completion date	March 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05023135` - DeepView SnapShot Portable (DV-SSP): Device Training Study
Recruiting	`NCT03459547` - Soft Peri-implant Tissue Around Different Abutment Materials	N/A
Recruiting	`NCT05608187` - Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers	Phase 2
Active, not recruiting	`NCT03649308` - Negative Pressure Wound Therapy Compared to Traditional Care After Skin Grafting	N/A
Recruiting	`NCT04596124` - Effectiveness and Tolerability of Fitostimoline Plus Cream and Gauze vs Connettivina Bio Plus Cream and Gauze	N/A
Completed	`NCT03285542` - Prospective Randomized Trial of Dermabond Prineo in Total Knee Arthroplasty	N/A
Recruiting	`NCT05689775` - Reconstruction After Abdominoperineal Resection With Robot-assisted Harvest of VRAM Flap
Recruiting	`NCT05474911` - PILONIDAL SINUS: CONVENTIONAL CARE VERSUS NEGATIVE PRESSURE THERAPY.	N/A
Recruiting	`NCT04849143` - The Effectiveness of Stingless Bee Honey (Kelulut Honey) Versus Gel in Diabetic Wound Bed Preparation	N/A
Completed	`NCT03596112` - The Difference in Wound Size Reduction Comparing Two Frequently Used Wound Dressings in Everyday Care	N/A
Recruiting	`NCT05169814` - Micro/Nanobubbles (MNBs) for Treatment of Acute and Chronic Wounds	Early Phase 1
Completed	`NCT04545476` - Enhanced Secondary Intention Healing vs. Standard Secondary Intention Healing in Mohs Surgical Defects on the Head and Distal Lower Extremities	N/A
Completed	`NCT06020157` - Comparison of Simple and Continuous Suture Techniques in Oral Surgery	N/A
Recruiting	`NCT05133570` - Study Evaluating the Effectiveness of Treatment With Vista Care®, in Arterial Ulcers of the Lower Extremities
Recruiting	`NCT04901325` - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)	Phase 2
Withdrawn	`NCT03668665` - Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From the Thigh - A Study in "Split Wound Design"	Phase 3
Completed	`NCT03703479` - Effect of A-PRF After Removal of Wisdom Teeth	N/A
Recruiting	`NCT03204851` - Microlyte Dressing in the Management of Wounds	N/A
Recruiting	`NCT06117436` - Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients	Phase 2/Phase 3
Recruiting	`NCT05618912` - Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.